Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""International journal of antimicrobial agents [Int J Antimicrob Agents] NLMUID: 9111860"" wg kryterium: JN


Tytuł :
High carriage of ESBL-producing Enterobacteriaceae associated with sexual activity among men who have sex with men.
Autorzy :
van Bilsen WPH; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
van Dulm E; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands. Electronic address: .
Matser DA; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Linde I; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
van Duijnhoven DYTHP; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Prins PJM; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Prins PM; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Boyd DA; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands; HIV Monitoring Foundation, Amsterdam, the Netherlands.
van Dam DAP; Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan 09, pp. 106276. Date of Electronic Publication: 2021 Jan 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase 3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
Autorzy :
Johnson MG; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: .
Bruno C; Merck & Co., Inc., Kenilworth, NJ, USA.
Castanheira M; JMI Laboratories, North Liberty, IA, USA.
Yu B; Merck & Co., Inc., Kenilworth, NJ, USA.
Huntington JA; Merck & Co., Inc., Kenilworth, NJ, USA.
Carmelitano P; Merck & Co., Inc., Kenilworth, NJ, USA.
Rhee EG; Merck & Co., Inc., Kenilworth, NJ, USA.
De Anda C; Merck & Co., Inc., Kenilworth, NJ, USA.
Motyl M; Merck & Co., Inc., Kenilworth, NJ, USA.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan 09, pp. 106278. Date of Electronic Publication: 2021 Jan 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Dysbiosis of rat vagina is efficiently rescued by the vaginal microbiota transplantation or probiotic combination: Vaginal microbiota transplantation rescues dysbiosis in rat vagina.
Autorzy :
Chen T; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Xia C; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Hu H; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Wang H; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Tan B; Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, PR China.
Tian P; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Zhao X; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Wang L; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Han Y; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Deng KY; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Wei H; Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510080, PR China.
Xin HB; National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang, 330031, PR China.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan 09, pp. 106277. Date of Electronic Publication: 2021 Jan 09.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Passive immunization and its rebirth in the era of the COVID-19 pandemic.
Autorzy :
Pavia CS; Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA. Electronic address: .
Wormser GP; Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan 02, pp. 106275. Date of Electronic Publication: 2021 Jan 02.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Hoang VT; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Honoré S; Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.
Roussel Y; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Million M; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106241.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antiviral Agents*/therapeutic use
COVID-19*
Azithromycin/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Hoang VT; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106237.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*
Hydroxychloroquine*
Humans ; SARS-CoV-2
Opinia redakcyjna
Tytuł :
Doxycycline as an Alternative to Azithromycin in Elderly Patients.
Autorzy :
Malek AE; Department of Internal Medicine, Division of Infectious Diseases, The University of Texas Health Science Center at Houston McGovern Medical School, 6431 Fannin St., Houston, TX 77030, USA; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Electronic address: .
Granwehr BP; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106168.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Doxycycline/*therapeutic use
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Administration, Oral ; Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Drug Combinations ; Drug Repositioning ; Drug Substitution ; Drug Synergism ; Humans
Opinia redakcyjna
Tytuł :
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Autorzy :
Million M; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.
Roussel Y; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France.
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, VITROME, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106240.
Typ publikacji :
Letter; Meta-Analysis
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
RNA, Viral/*antagonists & inhibitors
SARS-CoV-2/*drug effects
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/diagnosis ; COVID-19/virology ; COVID-19 Testing ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Drug Synergism ; Humans ; Nasopharynx/virology ; RNA, Viral/genetics ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Statistics as Topic ; Viral Load/drug effects
Raport
Tytuł :
Can we use hydroxychloroquine to treat COVID-19 now?
Autorzy :
Chen J; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Liu D; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Yin L; Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Zhang L; Clinical Research Center for New Drugs, Shanghai Public Health Clinical Center, Shanghai, 201508, China.
Lu H; Department of Infectious Diseases and Immunology, Shanghai Public Health Clinical Center, Shanghai, 201508, China. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106173.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Humans ; Indoles/therapeutic use ; Interferon-alpha/therapeutic use ; Lopinavir/therapeutic use ; Ritonavir/therapeutic use ; Uncertainty
Opinia redakcyjna
Tytuł :
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Autorzy :
Goldman JD; Divisions of Infectious Disease and Organ Transplant, Swedish Medical Center, Seattle, WA, United States. Electronic address: .
Diaz G; Divisions of Infectious Disease, Providence Regional Medical Center, Everett WA, United States.
Urba WJ; Divisions of Hematology and Medical Oncology, Providence Cancer Institute Franz Clinic, Portland, OR, United States.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106174.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Humans ; Politics ; Uncertainty
Opinia redakcyjna
Tytuł :
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Honoré S; Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106236.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Interactions ; Drug Repositioning ; Drug Synergism ; Electrocardiography ; Humans ; Hyperkalemia/prevention & control ; Hypokalemia/prevention & control ; Long QT Syndrome/prevention & control
Opinia redakcyjna
Tytuł :
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Honoré S; Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.
Hoang VT; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106242.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*drug effects
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Interactions ; Drug Repositioning ; Drug Synergism ; Electrocardiography ; Humans ; Hyperkalemia/prevention & control ; Hypokalemia/prevention & control ; Long QT Syndrome/prevention & control ; Magnesium/administration & dosage ; Patient Safety ; RNA, Viral/antagonists & inhibitors ; RNA, Viral/genetics ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Autorzy :
Parra-Lara LG; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: .
Martinez-Arboleda JJ; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
Isaza-Pierotti DF; Harvard Medical School, Boston, MA, USA.
Rosso F; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia; Infectious Diseases Service, Department of Internal Medicine, Fundación Valle del Lili, Cali, Colombia; Centro de Investigaciones Clínicas (CIC), Fundación Valle del Lili, Cali, Colombia.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106172.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Drug Synergism ; Humans ; Statistics as Topic ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Autorzy :
Nguyen TV; Garvan Institute of Medical Research, and University of Technology, Sydney, Australia. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106169.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Drug Combinations ; Drug Repositioning ; Humans ; Statistics as Topic ; Uncertainty
Opinia redakcyjna
Tytuł :
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Autorzy :
Dos Santos MR; Instituto do Coração do Hospital das Clínicas da Universidade de São Paulo (InCor HC-FMUSP), Brazil. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106176.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Humans ; Uncertainty
Opinia redakcyjna
Tytuł :
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Hoang VT; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106239.
Typ publikacji :
Clinical Trial; Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
COVID-19 Testing/*methods
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*drug effects
Aged ; Aged, 80 and over ; Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/mortality ; COVID-19/virology ; Drug Combinations ; Drug Repositioning ; Drug Synergism ; Female ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Nasopharynx/virology ; RNA, Viral/genetics ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Survival Analysis ; Treatment Outcome ; Viral Load/drug effects
Raport
Tytuł :
Advanced statistical methods and designs for clinical trials for COVID-19.
Autorzy :
Shan G; Epidemiology and Biostatistics Program, Department of Environmental and Occupational Health, School of Public Health, University of Nevada Las Vegas, Las Vegas, 89154, NV, USA. Electronic address: .
Wang W; Department of Mathematics and Statistics, Wright State University, Dayton, OH 45435, USA. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106167.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*pathogenicity
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Drug Synergism ; Humans ; Statistics as Topic
Opinia redakcyjna
Tytuł :
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Autorzy :
Colson P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
La Scola B; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106238.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
COVID-19 Testing/*methods
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*drug effects
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Repositioning ; Drug Synergism ; Humans ; Nasopharynx/virology ; RNA, Viral/genetics ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Treatment Outcome ; Viral Load/drug effects
Opinia redakcyjna
Tytuł :
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Lagier JC; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Honoré S; Service Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de Pharmacie Clinique, Aix Marseille Université, Marseille, France.
Hoang VT; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Colson P; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106243.
Typ publikacji :
Letter
MeSH Terms :
Antiviral Agents/*therapeutic use
Azithromycin/*therapeutic use
COVID-19/*drug therapy
Hydroxychloroquine/*therapeutic use
SARS-CoV-2/*drug effects
Anti-Bacterial Agents/therapeutic use ; Antimalarials/therapeutic use ; COVID-19/virology ; Clinical Trials as Topic ; Drug Combinations ; Drug Interactions ; Drug Repositioning ; Drug Synergism ; Electrocardiography ; Humans ; Long QT Syndrome/prevention & control ; Monitoring, Physiologic ; Patient Safety ; RNA, Viral/antagonists & inhibitors ; RNA, Viral/genetics ; SARS-CoV-2/genetics ; SARS-CoV-2/pathogenicity ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Response to advances statistical methods and designs for clinical trials for COVID-19.
Autorzy :
Gautret P; IHU-Méditerranée Infection, Marseille, France.; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Hoang VT; IHU-Méditerranée Infection, Marseille, France.; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France; Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam.
Lagier JC; IHU-Méditerranée Infection, Marseille, France.; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.
Raoult D; IHU-Méditerranée Infection, Marseille, France.; Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France. Electronic address: .
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan; Vol. 57 (1), pp. 106235.
Typ publikacji :
Letter; Comment
MeSH Terms :
COVID-19*
Humans ; SARS-CoV-2
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies